Reduction in serum aquaporin-4 antibody titers during development of a tumor-like brain lesion in a patient with neuromyelitis optica: A serum antibody-consuming effect?

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 3, 2015, Pages 194-197

  Aboulenein Djamshidian, Fahmy ^a   Höftberger, Romana ^a   Waters, Patrick ^c   Krampla, Wolfgang ^a   Lassmann, Hans ^b   Budka, Herbert ^a   Vincent, Angela ^c   Kristoferitsch, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Medical University of Vienna   (Austria)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Aquaporin 4; Brain biopsy; Multiple sclerosis; Neuromyelitis optica; Serum level; Tumor like lesion

Indexed keywords

AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; GADOLINIUM; IMMUNOGLOBULIN G ANTIBODY; LIVER ENZYME; METHYLPREDNISOLONE; PREDNISOLONE; ANTI-IGG; ANTIIDIOTYPIC ANTIBODY; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ADULT; AGITATION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BRAIN BIOPSY; BRAIN CYST; BRAIN DAMAGE; BRAIN NECROSIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPLEMENT ACTIVATION; CONFOCAL LASER MICROSCOPY; CONTRAST ENHANCEMENT; CORPUS CALLOSUM; CORTICOSTEROID THERAPY; CYSTIC SEMINECROTIZING TUMOR LIKE BRAIN LESION; DEPTH PERCEPTION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHIL; FEMALE; FOLLOW UP; HEMIANOPIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; MONOCYTE; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PATHOGENESIS; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIDE EFFECT; SPASTIC PARAPLEGIA; TREATMENT DURATION; BLOOD; BRAIN NEOPLASMS; NEUROMYELITIS OPTICA;

ANTIBODIES, ANTI-IDIOTYPIC; AQUAPORIN 4; BIOMARKERS; BRAIN NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; NEUROMYELITIS OPTICA;

EID: 84923641072     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000173     Document Type: Article

References (17)

1. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-89
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-12
3. Krampla W, Aboul-Enein F, Jecel J, et al. Spinal cord lesions in patients with neuromyelitis optica: A retrospective long-Term MRI follow-up study. Eur Radiol 2009;9:2535-43
4. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aqaporin-4 in the long term course of neuromyelitis optica. Brain 2008;131:3072-80
5. Aboul-Enein F, Seifert-Held T, Mader S, et al. Neuromyelitis optica in Austria in 2011: To bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One 2013;8: e79649. doi: 10.1371/journal.pone.0079649
6. Aboul-Enein F, Krssak M, Hoftberger R, et al. Diffuse white matter damage is absent in neuromyelitis optica. AJNR Am J Neuroradiol 2010; 31:76-79
7. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008;65:913-19
8. Aboul-Enein F, Weiser P, Hoftberger R, et al. Transient axonal injury in the absence of demyelination: A correlate of clinical disease in acute experimental autoimmune encephalomyelitis. Acta Neuropathol 2006;111: 539-47
9. Piddlesden SJ, Lassmann H, Zimprich F, et al. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143:555-64
10. Aboul-Enein F, Hoftberger R, Buxhofer-Ausch V, et al. Neocortical neurones may be targeted by immune attack in anti-Yo paraneoplastic syndrome. Neuropathol Appl Neurobiol 2008;34:248-52
11. Mader S, Lutterotti A, Di Pauli F, et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 2010; 5(5):e10455. doi: 10.1371/journal.pone.0010455
12. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-68
13. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-31
14. Sinclair C, Kirk J, Herron B, et al. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-Appearing white matter. Acta Neuropathol 2007; 113:187-94
15. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61
16. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: Distinction from multiple sclerosis. Brain 2007; 130:1224-34
17. Takahashi T, Fujihara K, Nakashima I, et al. AntiYaquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007;130:1235-43